As management has shown their ineptitude, why not wait till it gets closer to closing their doors then buy it considerable lower. No insiders seem to have confidence thus no salary is being reduced as a swap for share options. If the top employees don't want to own this why should I.
How many thought that at 7, or 5 or 3+. Unless management takes all their bonuses in stock- they are telling you what it is worth.
lost some sales overseas, but do not know if NVS sells Glatopa outside USA. USA sales of Copaxone did not decline very much. Am wondering if NVS did some channel stuffing at the end of last qtr, if they did would hurt prospects for this qtr.Also would explain why CW could not give any guidance going forward. Will find out next month what the numbers really are.
Did having a generic against the once daily effect sales numbers- haven't heard of any big hits and they have 69% on the longer lasting version, so noise but not much substance. Anyone know when the will do their share offering for the last big purchase of Allergans generic buis? thx
Operating income amounted to USD 317 million (+17%, +33% cc). Core operating income grew 4% (+17% cc) to USD 433 million, due to strong base business and launch performance. Core operating income margin increased 1.2 percentage points to 18.6% of net sales, as strong operating performance more than offset the high margin sales of the Diovan monotherapy authorized generic in the prior-year quarter. Note launch performance comment, Things that make you go hhmm.
Sandoz net sales reached USD 2.3 billion (-3%, +9% cc) in the third quarter, as volume growth of 21 percentage points more than compensated for 12 percentage points of price erosion (6 percentage points excluding Diovan monotherapy). Global sales of Biopharmaceuticals (which include biosimilars, biopharmaceutical contract manufacturing and Glatopa) grew 28% (cc) to USD 186 million, including continued progress of the newly launched Glatopa. Anti-Infectives franchise sales (consisting of partner label and finished dosage form sales) were up 15% (cc) to USD 349 million. Will say OK not spectacular.
Then why move asset to partnership and pay out to stakeholders any cash. keep asset and plow the cash back into more acreage while these prices are cheap. Then after a year (mark my post) instead of being in the 20's it could be much much more. Most of the players that have big payouts have had to curtail payments some eliminating them. so these guys are smarter than all the others? We will see next Oct.
New flow battery discovery on Psy. org site. shows why a company should not marry any one technology, alot of time and money being put into Battery Tech.
Did anybody see the doubling of EES buis (495Mw in Feb to 1 Gig today) nice increase in my opinion.
thx MBB for input, allways find it hard to get scipps info. Still think it will be good long embrace.
Sounds like counting chickens before they hatch. Maybe some clarity Sept 17-18th , either from Novartis or Momenta investor presentations- but not holding my breath.